Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.

Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ.

JAMA Netw Open. 2019 Jul 3;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562.

2.

Association Between Androgen Deprivation Therapy and Risk of Dementia.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH.

JAMA Oncol. 2017 Jan 1;3(1):49-55. doi: 10.1001/jamaoncol.2016.3662.

PMID:
27737437
3.

Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.

Nguyen C, Lairson DR, Swartz MD, Du XL.

Pharmacotherapy. 2018 Oct;38(10):999-1009. doi: 10.1002/phar.2168. Epub 2018 Sep 4.

PMID:
30080934
4.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

5.

Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.

Baik SH, Kury FSP, McDonald CJ.

J Clin Oncol. 2017 Oct 20;35(30):3401-3409. doi: 10.1200/JCO.2017.72.6109. Epub 2017 Aug 25.

6.

Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.

JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638.

PMID:
23860987
7.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.

BJU Int. 2016 Aug;118(2):221-9. doi: 10.1111/bju.13203. Epub 2015 Jul 22.

8.

No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.

Kao LT, Lin HC, Chung SD, Huang CY.

Asian J Androl. 2017 Jul-Aug;19(4):414-417. doi: 10.4103/1008-682X.179528.

9.

Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.

Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K.

J Clin Oncol. 2015 Mar 1;33(7):716-22. doi: 10.1200/JCO.2014.57.2743. Epub 2015 Jan 5.

10.

Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.

Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC.

Andrology. 2016 May;4(3):481-5. doi: 10.1111/andr.12187. Epub 2016 Apr 7.

11.

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.

Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.

Eur Urol. 2016 Jan;69(1):50-7. doi: 10.1016/j.eururo.2015.05.009. Epub 2015 May 21.

PMID:
26004800
12.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

PMID:
30326032
13.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

PMID:
30320443
14.

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.

Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.

JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.

15.

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.

Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L.

J Clin Oncol. 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.

PMID:
27870566
16.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW.

JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829. Erratum in: JAMA Oncol. 2015 Jul;1(4):544.

17.

Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression.

Kim JH, Lee B, Han DH, Chung KJ, Jeong IG, Chung BI.

Oncotarget. 2017 Aug 22;8(42):73087-73097. doi: 10.18632/oncotarget.20391. eCollection 2017 Sep 22.

18.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
19.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jul;124(1):87-92. doi: 10.1111/bju.14666. Epub 2019 Feb 6.

PMID:
30637900
20.

Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.

Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.

Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.

PMID:
26699831

Supplemental Content

Support Center